Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature

Hepatology

Volumn 59, Issue 6, 2014, Pages 2228-2237

  Malouf, Gabriel G ^a   Job, Sylvie ^b   Paradis, Valérie ^a   Fabre, Monique ^c   Brugières, Laurence ^c   Saintigny, Pierre ^d   Vescovo, Laure ^b   Belghiti, Jacques ^a   Branchereau, Sophie ^e   Faivre, Sandrine ^a   de Reyniès, Aurélien ^b   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

^b Ligue Nationale Contre le Cancer   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF TEXAS   (United States)

^e BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FURIN; NEUROTENSIN; PROHORMONE CONVERTASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOPLASM; FEMALE; FIBROLAMELLAR HEPATOCELLULAR CARCINOMA; GENE; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; UPREGULATION;

ADULT; CALCITONIN; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-2; GLYCOLYSIS; HUMANS; LIVER NEOPLASMS; MALE; NERVE TISSUE PROTEINS; NEUROTENSIN; PROPROTEIN CONVERTASE 1; RECEPTOR, ERBB-2; RECEPTORS, CELL SURFACE; TRANSCRIPTION, GENETIC;

EID: 84901427888     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27018     Document Type: Article

References (44)

1. Ward SC, Waxman S. Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis 2011;31:61-70.
2. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol 2007;14:217-223.
3. Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child 1956;91:168-186.
4. Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg 2012;215:820-830.
5. Torbenson M. Fibrolamellar carcinoma: 2012 update. Scientifica 2012. Available at: http://www.hindawi.com/journals/scientifica/2012/743790/abs/.
6. Malouf GG, Brugières L, Le Deley MC, Faivre S, Fabre M, Paradis V, et al. Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. Cancer 2012;118:4981-4990.
7. Malouf G, Falissard B, Azoulay D, Callea F, Ferrell LD, Goodman ZD, et al. Is histological diagnosis of primary liver carcinomas with fibrous stroma reproducible among experts?. J Clin Pathol 2009;62:519-524.
8. Ross HM, Daniel HDJ, Vivekanandan P, Kannangai R, Yeh MM, Wu TT, et al. Fibrolamellar carcinomas are positive for CD68. Mod. Pathol 2011;24:390-395.
9. Payne CM, Nagle RB, Paplanus SH, Graham AR. Fibrolamellar carcinoma of liver: a primary malignant oncocytic carcinoid?. Ultrastruct Pathol 1986;10:539-552.
10. Lloreta J, Vadell C, Fabregat X, Serrano S. Fibrolamellar hepatic tumor with neurosecretory features and systemic deposition of AA amyloid. Ultrastruct Pathol 1994;18:287-292.
11. Tallini G. Oncocytic tumours. Virchows Arch 1998;433:5-12.
12. Vivekanandan P, Daniel H, Yeh MM, Torbenson M. Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas. Mod Pathol 2010;23:790-798.
13. Brunel V, Cauliez B, Lacaze L, Riachi G, Gargala G, Francois A, et al. Liver mass in a young adult. Lancet 2011;378:1196.
14. Collier NA, Weinbren K, Bloom SR, Lee YC, Hodgson HJ, Blumgart LH. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet 1984;1:538-540.
15. Ehrenfried JA, Zhou Z, Thompson JC, Evers BM. Expression of the neurotensin gene in fetal human liver and fibrolamellar carcinoma. Ann Surg 1994;220:484-489; discussion, 489-491.
16. Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 2010;23:1180-1190.
17. Jansen E, Ayoubi TA, Meulemans SM, Van de Ven WJ. Neuroendocrine-specific expression of the human prohormone convertase 1 gene. Hormonal regulation of transcription through distinct cAMP response elements. J Biol Chem 1995;270:15391-15397.
18. Kajiwara H, Itoh Y, Itoh J, Yasuda M, Osamura RY. Immunohistochemical expressions of prohormone convertase (PC)1/3 and PC2 in carcinoids of various organs. Tokai J Exp Clin Med 1999;24:13-20.
19. Wilson ME, Kalamaras JA, German MS. Expression pattern of IAPP and prohormone convertase 1/3 reveals a distinctive set of endocrine cells in the embryonic pancreas. Mech Dev 2002;115:171-176.
20. Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52.
21. Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard CA, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008;14:471-484.
22. Kannangai R, Vivekanandan P, Martinez-Murillo F, Choti M, Torbenson M. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol 2007;38:639-644.
23. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010;70:10202-10212.
24. Wurmbach E, Chen Y, Khitrov G, Zhang W, Roayaie S, Schwartz M, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007;45:938-947.
25. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
26. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118-127.
27. Huang Y, Niu B, Gao Y, Fu L, Li W. CD-HIT Suite: a web server for clustering and comparing biological sequences. Bioinformatics 2010;26:680-682.
28. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
29. Gogvadze V, Zhivotovsky B, Orrenius S. The Warburg effect and mitochondrial stability in cancer cells. Mol Aspects Med 2010;31:60-74.
30. Kim J, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-185.
31. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006;3:187-197.
32. Porcelli AM, Ghelli A, Ceccarelli C, Lang M, Cenacchi G, Capristo M, et al. The genetic and metabolic signature of oncocytic transformation implicates HIF1alpha destabilization. Hum Mol Genet 2010;19:1019-1032.
33. Badache A, Hynes NE. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 2004;5:299-301.
34. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009;19:156-172.
35. Moss AC, Jacobson GM, Walker LE, Blake NW, Marshall E, Coulson JM. SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer. Clin Cancer Res 2009;15:274-283.
36. Hald J, Galbo T, Rescan C, Radzikowski L, Sprinkel AE, Heimberg H, et al. Pancreatic islet and progenitor cell surface markers with cell sorting potential. Diabetologia 2012;55:154-165.
37. Deutsch G, Jung J, Zheng M, Lóra J, Zaret KS. A bipotential precursor population for pancreas and liver within the embryonic endoderm. Development 2001;128:871-881.
38. Pieler T, Chen Y. Forgotten and novel aspects in pancreas development. Biol Cell 2006;98:79-88.
39. Rao MS, Scarpelli DG, Reddy JK. Transdifferentiated hepatocytes in rat pancreas. Curr Top Dev Biol 1986;20:63-78.
40. Lee BC, Hendricks JD, Bailey GS. Metaplastic pancreatic cells in liver tumors induced by diethylnitrosamine. Exp Mol Pathol 1989;50:104-113.
41. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006;25:4777-4786.
42. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res 2006;66:6087-6096.
43. Gasparre G, Hervouet E, de Laplanche E, Demont J, Pennisi LF, Colombel M, et al. Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet 2008;17:986-995.
44. Ding Y, Liu Z, Desai S, Zhao Y, Liu H, Pannell LK, et al. Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism. Nat Commun 2012;3:1271.